Get informed when a big investor buys or sells
+ Follow-91.55%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Kalaris Therapeutics (KLRS) currently reports a ROE of -91.55%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Kalaris Therapeutics's ROE history and peer comparisons.
Kalaris Therapeutics's ROE of -91.55% is lower than the Healthcare sector average of 13.1%. That is roughly 798.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Kalaris Therapeutics's current -91.55% should be judged against Healthcare norms (sector average: 13.1%) and against KLRS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -91.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Kalaris Therapeutics, and consider following KLRS for alerts when major investors trade the stock.
Kalaris Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -91.55% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KLRS with unrelated industries.